Dr. Aplenc is a Professor of Pediatrics in the Department of Pediatrics with a secondary appointment in the Department of Biostatistics, Informatics, and Epidemiology. His research focus is in pediatric acute myeloid leukemia (AML) with ongoing clinical epidemiology and translational research projects. Dr. Aplenc's current clinical epidemiology research focuses on chemotherapy associated cardiac toxicity and disparities in treatment outcomes for children with AML. From a translational research standpoint, he lead efforts to identify genetic predictors of anthracycline associated cardiac toxicity and to characterize the AML blast cell surfaceome to identify novel therapeutic targets for pediatric AML. From a clinic trial perspective, he co-Chair the Pediatric Blood and Marrow Transplant Consortium trial for an anti-CD33 chimeric antigen receptor (CAR) and is also the PI of a local anti-CD123 CAR trial. In addition, he serves as the Vice-Chair of the Children's Oncology Group AML Strategy Committee.